Up to 40 % of acute ischaemic strokes in young adults are cryptogenic in nature, that is, no cause is determined. In more than half of these patients, patent foramen ovale (PFO) is seen along with an increased incidence of atrial septal aneurysm. The commonest method of investigation is echocardiography (preferably transoesophageal echocardiography). On the basis of available evidence, low risk patients are treated with antiplatelet agents and high risk patients with warfarin. There are inconclusive data on the efficacy of PFO closure to prevent stroke recurrence. However, if there is recurrent stroke or intolerance to medical therapy, percutaneous closure is carried out. See end of article for authors ’ affiliation
peer reviewedRATIONALE: Currently available data do not provide definitive evidence on the comparati...
Previous systematic reviews and meta-analyses compared the efficacy and safety of patent foramen ova...
We read with interest the report by Markus et al of the CARESS trial,1 in which dual antiplatelet th...
The authors have no financial conflicts of interest. The importance of intracranial atherosclerotic ...
A transient ischemic attack (TIA) is an opportunity for stroke prevention. We examined the care of 7...
foramen ovale closure and brain ischaemic lesions To the Editor The recently published meta-analysis...
Full list of author information is available at the end of the articlein nature [1-5]. Multiple obse...
Objective: The goal of this study was to evaluate the utility of the stroke thrombolytic predictive ...
Objective: To determine if there are evidences of a causal relation between patent foramen ovale (PF...
In Dr Spiegel’s opinion, our registry study of 182 678 patients with atrial fibrillation (AF) offers...
BackgroundaaAcute ischemic stroke secondary to aortic dissection (AoD) is challenging in the era of ...
The author offers more evidence to support Zhang\u27s assertion in CRP 3(2) that closure of patent f...
D ow nloaded from DOI: 10.1161/CIRCULATIONAHA.113.005540 2 My grandmother used to say: “If a little’...
BACKGROUND: Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic str...
Background: A significant proportion of ischaemic stroke episodes are caused by atherosclerotic lesi...
peer reviewedRATIONALE: Currently available data do not provide definitive evidence on the comparati...
Previous systematic reviews and meta-analyses compared the efficacy and safety of patent foramen ova...
We read with interest the report by Markus et al of the CARESS trial,1 in which dual antiplatelet th...
The authors have no financial conflicts of interest. The importance of intracranial atherosclerotic ...
A transient ischemic attack (TIA) is an opportunity for stroke prevention. We examined the care of 7...
foramen ovale closure and brain ischaemic lesions To the Editor The recently published meta-analysis...
Full list of author information is available at the end of the articlein nature [1-5]. Multiple obse...
Objective: The goal of this study was to evaluate the utility of the stroke thrombolytic predictive ...
Objective: To determine if there are evidences of a causal relation between patent foramen ovale (PF...
In Dr Spiegel’s opinion, our registry study of 182 678 patients with atrial fibrillation (AF) offers...
BackgroundaaAcute ischemic stroke secondary to aortic dissection (AoD) is challenging in the era of ...
The author offers more evidence to support Zhang\u27s assertion in CRP 3(2) that closure of patent f...
D ow nloaded from DOI: 10.1161/CIRCULATIONAHA.113.005540 2 My grandmother used to say: “If a little’...
BACKGROUND: Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic str...
Background: A significant proportion of ischaemic stroke episodes are caused by atherosclerotic lesi...
peer reviewedRATIONALE: Currently available data do not provide definitive evidence on the comparati...
Previous systematic reviews and meta-analyses compared the efficacy and safety of patent foramen ova...
We read with interest the report by Markus et al of the CARESS trial,1 in which dual antiplatelet th...